Reyvow: A Treatment For Migraine

The approval of Reyvow has been very significant as it is an innovation in the treatment of acute migraine by the FDA in more than two decades.  Reyvow is a drug composed of the active substance that is lasmiditan. It has a different mechanism of action than other drugs used in the acute treatment of migraine.

It is a new class of treatment in cases of acute migraine, its novelty is that it is the only drug in the family approved by the FDA. It is an agonist of the 5-HT1F receptor, for this reason, it exerts its action both centrally and peripherally.

Several studies have been carried out, the results of which have revealed that a higher percentage of patients treated with Reyvow did not experience a migraine within two hours of the first dose, compared to study participants who took placebo.

What is migraine?

Migraine is a type of severe headache that generally affects women more. It is a headache located more frequently in the middle of it, and is usually accompanied by other symptoms.

Symptoms linked to migraine include auras with nausea, vomiting, or sensitivity to light. Some migraines appear without aura, however, those that do have it, on many occasions prevent those affected from continuing with their life and significantly decrease the quality of it.

It is common for migraine patients to experience several phases of treatment. It is even recommended to combine drug treatment with alternative therapies or techniques, to try to take fewer drugs and thus avoid their side effects.

Is Reyvow safe?

The medicine is available as tablets with two different strengths, 50 mg and 100 mg doses. As for its most frequent adverse effects are dizziness, fatigue, sedation, nausea, vomiting and muscle weakness.

In addition, as the drug exerts action at the central nervous system level, while you are in treatment, it is advisable not to drive or do tasks that require a lot of attention. For this reason, you also need to be careful if you have to operate machinery for at least eight hours after taking Reyvow.

How does it work?

Lasmiditan binds to the 5-HT1F receptor and acts both centrally and peripherally. It exerts its action by reducing the release of substances called neuropeptides. In addition, it influences pain pathways without vasoconstriction at the brain level.

This drug has been approved by the results obtained in Phase III studies in which a total of 3 177 patients who had suffered migraines both with and without aura participated. 

The FDA noted that the data obtained revealed that the percentage of patients whose symptoms were pain, nausea and sensitivity to light, was significantly lower among patients taking lasmiditan.

In just two hours, and with a single dose, this drug has been able to quickly and completely eliminate pain. It is also effective in the control and relief of symptoms associated with migraine such as auras.

Reyvow and migraine

Having a migraine episode can make you unable to do daily tasks. People who suffer from migraines experience attacks that can be very intense and painful, so they are forced to stop daily activities. 

With just one dose, Reyvow provides the ability to quickly and completely eliminate moderate to severe migraine pain in just two hours. 

Reyvow is not an opioid or narcotic drug, based on the data available at this time, its use does not create physical dependence.

Adverse effects

In general, the side effects that may appear while taking this medicine are mild or moderate. The symptoms that may appear more frequently are:

• Dizziness
• Fatigue.
• S tingling or numbness.
• Drowsiness.
• Nausea and vomiting

Other precautions to consider include the possibility of developing central nervous system depression or serotonin syndrome.

           Also read: Alternatives to relieve migraine

The difficulty of treating migraine

Reyvow is a medicine that reduces a moderate or severe headache within two hours of taking it. It also has the advantage of not producing photophobia or nausea. Currently, it represents an advance in the treatment of migraines, making it a good option for these patients.